<DOC>
	<DOCNO>NCT01662310</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , tolerability safety paliperidone extend release ( ER ) tablet ( 3 12 milligram ( mg ) , day ) prevention relapse schizophrenia participant .</brief_summary>
	<brief_title>An Efficacy Study Paliperidone Prevention Relapse Participants With Schizophrenia</brief_title>
	<detailed_description>This double-blind ( neither physician participant know name assigned drug ) , randomize ( participant assign treatment chance ) , placebo-controlled , parallel-group study paliperidone ER tablet . The study consist 6 phase : 14 day screen phase , 8 week open-label run-in phase ( participant flexibly dose paliperidone ER daily dose range 3 mg 12 mg ) , 6 week stabilization phase ( participant continue receive fix dose paliperidone ER ) , double-blind ( DB ) phase various length ( participant randomly assign 1:1 ratio receive either paliperidone ER placebo phase complete 86 relapse event observe study positive interim analysis ) , 6 month open-label extension ( participant experience relapse event remain relapse free entire duration double-blind phase participant enrol time study terminate , eligible phase . All participant treat paliperidone ER safety tolerability information collect phase ) phase 6 month follow-up phase ( participant withdraw DB phase reason relapse follow 6 month experience relapse ) . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Have diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) Have experience acute episode , Positive Negative Syndrome Scale ( PANSS ) total score 70 120 inclusive , Screening Baseline Women must postmenopausal ( least 1 year ) , surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation , otherwise incapable pregnancy ) , practice highly effective method birth control , sexually active Men must use highly effective method birth control must donate sperm study 3 month receive last dose study drug Be willing capable complete questionnaire able take oral medication independently Has drug dependence diagnosis accord DSMIV ( exclude nicotine caffeine dependence ) within 6 month screen Participants Crohn 's disease hepatic renal disease Has relevant history significant and/or unstable cardiovascular , respiratory , neurologic ( include seizure significant cerebrovascular dysfunction ) , renal , hepatic , endocrine , immunologic disease Has history neuroleptic malignant syndrome ( disorder cause antipsychotic drug symptom fever , muscle rigidity delirium ) Has know suspect Stevens Johnson Syndrome ( immune disease symptom fever , sore throat , ulcer conjunctivitis ) exposure phenytoin , carbamazepine , barbiturate , lamotrigine Had treat clozapine treatment refractory treatment resistant schizophrenia Has significant risk suicide homicidal behavior , significant risk deliberate self harm harm others Has take isocarboxazid , phenelzine , selegiline tranylcypromine within 4 week screening Has receive electroconvulsive therapy within 60 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Paliperidone Extended-Release</keyword>
</DOC>